Emergent BioSolutions (EBS) Competitors

Emergent BioSolutions (NYSE:EBS) and Dynavax Technologies (NASDAQ:DVAX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, community ranking, institutional ownership, earnings, valuation and profitability.

Which has better valuation & earnings, EBS or DVAX?

Dynavax Technologies has lower revenue, but higher earnings than Emergent BioSolutions. Dynavax Technologies is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent BioSolutions	$930.30M	0.40	-$760.50M	-$2.71	-2.51
Dynavax Technologies	$294.62M	4.21	-$6.39M	-$0.52	-19.85

Do institutionals & insiders hold more shares of EBS or DVAX?

78.4% of Emergent BioSolutions shares are owned by institutional investors. Comparatively, 97.0% of Dynavax Technologies shares are owned by institutional investors. 3.2% of Emergent BioSolutions shares are owned by insiders. Comparatively, 3.0% of Dynavax Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Do analysts recommend EBS or DVAX?

Emergent BioSolutions presently has a consensus target price of $14.33, suggesting a potential upside of 110.63%. Dynavax Technologies has a consensus target price of $24.00, suggesting a potential upside of 132.49%. Given Dynavax Technologies' higher possible upside, analysts plainly believe Dynavax Technologies is more favorable than Emergent BioSolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent BioSolutions	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Dynavax Technologies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the media refer more to EBS or DVAX?

In the previous week, Emergent BioSolutions had 5 more articles in the media than Dynavax Technologies. MarketBeat recorded 11 mentions for Emergent BioSolutions and 6 mentions for Dynavax Technologies. Dynavax Technologies' average media sentiment score of 1.31 beat Emergent BioSolutions' score of 0.31 indicating that Dynavax Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Emergent BioSolutions	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dynavax Technologies	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Is EBS or DVAX more profitable?

Dynavax Technologies has a net margin of 9.85% compared to Emergent BioSolutions' net margin of -18.55%. Dynavax Technologies' return on equity of 4.22% beat Emergent BioSolutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent BioSolutions	-18.55%	-9.91%	-3.31%
Dynavax Technologies	9.85%	4.22%	2.67%

Does the MarketBeat Community favor EBS or DVAX?

Dynavax Technologies received 48 more outperform votes than Emergent BioSolutions when rated by MarketBeat users. However, 66.82% of users gave Emergent BioSolutions an outperform vote while only 65.79% of users gave Dynavax Technologies an outperform vote.

Company	Underperform	Outperform
Emergent BioSolutions	Outperform Votes 429 66.82%	Underperform Votes 213 33.18%
Dynavax Technologies	Outperform Votes 477 65.79%	Underperform Votes 248 34.21%

Which has more risk & volatility, EBS or DVAX?

Emergent BioSolutions has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500. Comparatively, Dynavax Technologies has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.

Summary

Dynavax Technologies beats Emergent BioSolutions on 11 of the 17 factors compared between the two stocks.